Peptide vaccine targeting mutated <i>GNAS</i>: a potential novel treatment for pseudomyxoma peritonei

Abstract

These findings point to the existence of a pre-existing immunity in patients with PMP towards mutated Gsα, which has been insufficient to control tumor growth, possibly because of inhibition of antitumor T cells by upregulation of immune checkpoint molecules. The results form a rationale for exploring peptide vaccination with Gsα peptides in combination with immune checkpoint inhibiton as a possible curative treatment for PMP and other <i>GNAS</i> mutated cancers.